PD-1 inhibitor-induced rheumatic, endocrine, and sarcoidosis-like immune-related adverse events in metastatic melanoma are associated with improved survival and lower corticosteroid exposure
Rheumatic, endocrine, and sarcoidosis-like irAEs are markers of superior survival and suggest that lower initial corticosteroid doses may preserve PD-1 inhibitor efficacy.
Authors
- Maria Salete Sandini Linden (ORCID: https://orcid.org/0000-0001-6501-1710)
- Levent M. Akyürek (ORCID: https://orcid.org/0000-0002-1968-6458)
- Ankur Pandita (ORCID: https://orcid.org/0000-0003-4801-1211)
- Hifaa Al Remawi
- Anna Fager (ORCID: https://orcid.org/0009-0003-6443-5345)
- L Ny
- Max Levin
- Anna Rudin
- Sara Bjursten
Institutions
- Sahlgrenska University Hospital (SE)
- University of Gothenburg (SE)
Publication Details
- Journal
- Immunotherapy Advances
- Published
- 2025-12-31
- DOI
- https://doi.org/10.1093/immadv/ltag004
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Swedish Cancer Foundation
- Cancerfonden
- Vetenskapsrådet
- Stiftelsen Assar Gabrielssons Fond
- Stiftelsen Jubileumsklinikens Forskningsfond mot Cancer